Skip to content
Screener

Operating Income at other companies

Amgen logo
AmgenAMGN
$3.51B+32.3%
Incyte logo
IncyteINCY
$697.9M+31.6%
AbbVie logo
AbbVieABBV
$6.43B+31.4%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$75.61M+10.6%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-$36.43M-45.2%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-$82.77M-31.2%

Other financials

Income statement

See full
Revenue$213.5M+3,749%
Net income$162.8M+568%
EPS (diluted)$2.29+516%

Balance sheet

See full
Cash & equivalents$420.1M+149%
Total debt$9.2M-18.3%
Total equity$841.5M+26.0%
Total assets$885.5M+23.3%

Cash flow

See full
Operating cash flow$219.1M
CapEx$168.0K-79.3%
Free cash flow$218.9M

Valuation

See full
Market cap$8.83B+165%
Enterprise value$8.42B+165%
P/E106.5×+42.4×
P/S31.3×+15.4×

Profitability

See full
Operating margin20.7%+9.2pp
Net margin29.4%+4.5pp
FCF margin-12,264.3%-12,527pp

Returns & leverage

See full
Return on equity11%+2.4pp
Debt / equity0.0×
Current ratio21.7×+4.7×

Where this comes from

Reported directly by Protagonist Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091123
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Research and development42,06137,03688,80072,929
General and administrative12,64810,55125,92522,289
Total operating expenses54,70947,587114,72595,218
Income (loss) from operations158,766(42,041)155,118(61,351)
Interest income6,4297,40612,30514,979
Other (expense) income, net(81)36(28)118
Income (loss) before income tax expense165,114(34,599)167,395(46,254)
Income tax expense2,265172763172

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Protagonist Therapeutics's operating income?
Protagonist Therapeutics (PTGX) reported operating income of $158.77M in Q2 2026.
How has Protagonist Therapeutics's operating income changed year-over-year?
Protagonist Therapeutics's operating income increased by 477.6% year-over-year, from -$42.04M to $158.77M.
What is the long-term trend for Protagonist Therapeutics's operating income?
Over 3 years (2021 to 2025), Protagonist Therapeutics's operating income has grown at a 7.9% compound annual growth rate (CAGR), from -$125.85M to -$158.13M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Protagonist Therapeutics's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude